Mefloquine, Moxifloxacin, and Ethambutol Are a Triple-Drug Alternative to Macrolide-Containing Regimens for Treatment of Mycobacterium avium Disease

Macrolides are the core of effective drug regimens for the treatment of Mycobacterium avium complex (MAC) disease. Mefloquine (MFQ), moxifloxacin (MXF), and ethambutol (EMB), in combination, were evaluated against both clarithromycin-resistant (CLR-R) and CLR-susceptible (CLR-S) MAC; MFQ (40 mg/kg),...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 2003-06, Vol.187 (12), p.1977-1980
Main Authors: Bermudez, Luiz E, Kolonoski, Peter, Petrofsky, Mary, Wu, Martin, Inderlied, Clark B, Young, Lowell S
Format: Article
Language:English
Subjects:
AIDS
Animals
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Anti-Infective Agents - pharmacology
Anti-Infective Agents - therapeutic use
Antibacterial agents
Antibacterials
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antimalarials - pharmacology
Antimalarials - therapeutic use
Aza Compounds
Bacteria
Biological and medical sciences
Clarithromycin - pharmacology
Disease Models, Animal
Drug Resistance, Bacterial
Drug Therapy, Combination
Ethambutol - pharmacology
Ethambutol - therapeutic use
Fluoroquinolones
Fungal infections
Infections
Liver
Lung diseases
Macrolides
Medical sciences
Mefloquine - pharmacology
Mefloquine - therapeutic use
Mice
Mycobacterium avium
Mycobacterium avium complex
Mycobacterium avium Complex - drug effects
Mycobacterium avium-intracellulare Infection - drug therapy
Mycobacterium avium-intracellulare Infection - microbiology
Pharmacology. Drug treatments
Quinolines
Spleen
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Macrolides are the core of effective drug regimens for the treatment of Mycobacterium avium complex (MAC) disease. Mefloquine (MFQ), moxifloxacin (MXF), and ethambutol (EMB), in combination, were evaluated against both clarithromycin-resistant (CLR-R) and CLR-susceptible (CLR-S) MAC; MFQ (40 mg/kg), MXF (100 mg/kg), or EMB (100 mg/kg/day) was given to mice for 4 weeks. MFQ was bactericidal, whereas MXF and EMB were bacteriostatic against both MAC 101 CLR-S and CLR-R. The combination of MFQ and EMB reduced (P
ISSN:0022-1899
1537-6613
DOI:10.1086/375352